Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.

@article{Mayer2006RatiometricDO,
  title={Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.},
  author={Lawrence D. Mayer and Troy O Harasym and Paul G. Tardi and Natashia L Harasym and Clifford R. Shew and Sharon A Johnstone and Euan C. Ramsay and Marcel Bally and Andrew S. Janoff},
  journal={Molecular cancer therapeutics},
  year={2006},
  volume={5 7},
  pages={
          1854-63
        }
}
Anticancer drug combinations can act synergistically or antagonistically against tumor cells in vitro depending on the ratios of the individual agents comprising the combination. The importance of drug ratios in vivo, however, has heretofore not been investigated, and combination chemotherapy treatment regimens continue to be developed based on the maximum tolerated dose of the individual agents. We systematically examined three different drug combinations representing a range of anticancer… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 112 CITATIONS, ESTIMATED 57% COVERAGE

Strategies for improving the therapeutic and diagnostic approaches to acute leukemias

Hyun Pyo Kim
  • 2011
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2006
2019

CITATION STATISTICS

  • 5 Highly Influenced Citations

  • Averaged 18 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES

Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
VIEW 16 EXCERPTS

Principles of cancer management: chemotherapy

VT DeVita, Jr.
  • July 2006 on June
  • 1997
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
VIEW 14 EXCERPTS
HIGHLY INFLUENTIAL

Dose: a critical factor in cancer chemotherapy.

  • The American journal of medicine
  • 1980
VIEW 14 EXCERPTS
HIGHLY INFLUENTIAL